

Supplementary Table 3. Co-medications frequently used by patients with or without a hospital admission record during the study period

Patients with a record of hospital admission (n=324)					Patients with no record of hospital admission (n=1121)				
Rank	Drug subgroup name	ATC Code	n	%	Rank	Drug subgroup name	ATC Code	n	%
1	Antacids, antilatulents and anti-ulcerants	A02	178	54.9%	1	Antacids, antilatulents and anti-ulcerants	A02	280	25.0%
2	Systemic antibacterials	J01	137	42.3%	2	Psycholeptics	N05	223	19.9%
3	Psycholeptics	N05	95	29.3%	3	Systemic antihistamines	R06	203	18.1%
4	Anti-inflammatory and anti-rheumatic products	M01	69	21.3%	4	Lipid-regulating/anti-atheroma preparations	C10	185	16.5%
5	Systemic antihistamines	R06	65	20.1%	5	Systemic antibacterials	J01	184	16.4%
6	Lipid-regulating/anti-atheroma preparations	C10	64	19.8%	6	Anti-inflammatory and anti-rheumatic products	M01	155	13.8%
7	Antithrombotic agents	B01	58	17.9%	7	Antidiarrhoeals, oral electrolyte replacers and intestinal anti-inflammatories	A07	120	10.7%
8	Agents acting on the renin-angiotensin system	C09	56	17.3%	8	Agents acting on the renin-angiotensin system	C09	104	9.3%
9	Antidiarrhoeals, oral electrolyte replacers and intestinal anti-inflammatories	A07	55	17.0%	9	Vitamins	A11	93	8.3%
10	Vitamins	A11	55	17.0%	10	Cough and cold preparations	R05	91	8.1%
11	Analgesics	N02	54	16.7%	11	Calcium antagonists	C08	80	7.1%
12	Systemic agents for fungal infections	J02	53	16.4%	12	Anti-gout preparations	M04	74	6.6%
13	Cough and cold preparations	R05	47	14.5%	13	All other therapeutic products	V03	53	4.7%
14	Calcium antagonists	C08	45	13.9%	14	Functional gastro-intestinal disorder drugs	A03	53	4.7%
15	Systemic corticosteroids	H02	44	13.6%	15	Cholagogues and hepatic protectors	A05	53	4.7%
16	All other therapeutic products	V03	43	13.3%	16	Analgesics	N02	52	4.6%
17	Intravenous solutions	K01	39	12.0%	17	Drugs used in diabetes	A10	49	4.4%
18	Functional gastro-intestinal disorder drugs	A03	38	11.7%	18	Psychoanaesthetics excluding anti-obesity preparations	N06	44	3.9%
19	Antivirals for systemic use	J05	38	11.7%	19	Antithrombotic agents	B01	40	3.6%
20	Anti-gout preparations	M04	38	11.7%	20	Anti-epileptics	N03	37	3.3%
21	Anti-epileptics	N03	38	11.7%	21	Anti-asthma and copd products	R03	35	3.1%
22	Drugs used in diabetes	A10	35	10.8%	22	Anti-anaemic preparations	B03	32	2.9%
23	Antiprotozoals and anthelmintics	P01	33	10.2%	23	Antiprotozoals and anthelmintics	P01	27	2.4%
24	Cholagogues and hepatic protectors	A05	30	9.3%	24	Systemic agents for fungal infections	J02	25	2.2%
25	Drugs for constipation and bowel cleansers	A06	29	9.0%	25	Drugs for constipation and bowel cleansers	A06	24	2.1%
26	Psychoanaesthetics excluding anti-obesity preparations	N06	26	8.0%	26	Systemic corticosteroids	H02	22	2.0%
27	Diuretics	C03	24	7.4%	27	Antivirals for systemic use	J05	22	2.0%
28	Anti-asthma and copd products	R03	19	5.9%	28	Beta-blocking agents	C07	22	2.0%
29	Blood coagulation system, other products	B02	18	5.6%	29	Urologicals	G04	21	1.9%
30	Anti-anaemic preparations	B03	18	5.6%	30	Diuretics	C03	18	1.6%
31	Beta-blocking agents	C07	15	4.6%	31	Other cns drugs	N07	18	1.6%
32	Urologicals	G04	15	4.6%	32	Muscle relaxants	M03	17	1.5%
33	Antimycobacterials	J04	14	4.3%	33	Thyroid therapy	H03	14	1.2%
34	Dietetic agents	V06	14	4.3%	34	Cardiac therapy	C01	11	1.0%
35	Other cns drugs	N07	13	4.0%	35	Blood coagulation system, other products	B02	10	0.9%
36	Cardiac therapy	C01	12	3.7%	36	Antimycobacterials	J04	10	0.9%
37	All other non-therapeutic products	V07	12	3.7%	37	Other drugs for disorders of the musculo-skeletal system	M05	10	0.9%
38	Mineral supplements	A12	8	2.5%	38	Antihypertensives	C02	8	0.7%
39	Injection solutions/infusion additives (<100ml)	K04	7	2.2%	39	Dietetic agents	V06	6	0.5%
40	Muscle relaxants	M03	7	2.2%	40	Other dermatological preparations	D11	6	0.5%
41	Antihypertensives	C02	6	1.9%	41	Digestives, including digestive enzymes	A09	5	0.4%
42	Other drugs for disorders of the musculo-skeletal system	M05	6	1.9%	42	Mineral supplements	A12	4	0.4%
43	Immunostimulating agents	L03	5	1.5%	43	Other cardiovascular products	C06	3	0.3%
44	Other cardiovascular products	C06	4	1.2%	44	Antifungals, dermatological	D01	3	0.3%
45	Antifungals, dermatological	D01	4	1.2%	45	Anti-parkinson drugs	N04	3	0.3%
46	Thyroid therapy	H03	4	1.2%	46	Cerebral and peripheral vasotherapeutics	C04	3	0.3%
47	Other hormones	H04	4	1.2%	47	Intravenous solutions	K01	2	0.2%
48	Anaesthetics	N01	4	1.2%	48	Topical corticosteroids	D07	2	0.2%
49	Anti-parkinson drugs	N04	4	1.2%	49	Other alimentary tract and metabolism products	A16	2	0.2%
50	Digestives, including digestive enzymes	A09	3	0.9%	50	Cytostatic hormone therapy	L02	2	0.2%
51	Antiemetics and antinauseants	A04	2	0.6%	51	Topical anti-rheumatics	M02	1	0.1%
52	Cerebral and peripheral vasotherapeutics	C04	2	0.6%	52	Antivaricosis/anti-haemorrhoidal preparations	C05	1	0.1%
53	Topical corticosteroids	D07	2	0.6%	53	Immunosuppressants	L04	1	0.1%
54	Gynaecological anti-infectives	G01	2	0.6%	54	Cardiovascular multitherapy combination products	C11	1	0.1%
55	Topical anti-rheumatics	M02	2	0.6%	55	Emollients, protectives	D02	1	0.1%
56	Stomatologicals, mouth preparations, medicinal dentifrices etc	A01	1	0.3%	56	Nonsteroidal products for inflammatory skin disorders	D05	1	0.1%
57	Anabolics, systemic	A14	1	0.3%	57	Anti-acne preparations	D10	1	0.1%
58	Antivaricosis/anti-haemorrhoidal preparations	C05	1	0.3%	58	Sex hormones and products with similar desired effects, systemic action only	G03	1	0.1%
59	Antiseptics and disinfectants	D08	1	0.3%	59	Ophthalmologicals	S01	1	0.1%
60	Antineoplastics	L01	1	0.3%	-	-	-	-	-
61	Immunosuppressants	L04	1	0.3%	-	-	-	-	-

Co-medications prescribed for use for ≥30 days total during the study period, regardless of whether they are inpatient/outpatient prescriptions, are listed.

Co-medications were classified based on the therapeutic subgroups (2nd level) of ATC codes.

Gray-shaded cells indicate the class of hospital solutions (categorized under "K" in EphMRA ATC).